283173-50-2
基本信息
卢卡帕尼
鲁卡帕尼
瑞卡帕布碱
卢卡帕尼杂质
卢卡帕尼杂质16
瑞卡帕布/鲁卡帕尼
8-氟-2-(4-((甲胺基)甲基)苯基)-4,5-二氢-1H-氮杂卓并[5,4,3-CD]吲哚-6(3H)-酮
8-氟-1,3,4,5-四氢-2-[4-[(甲基氨基)甲基]苯基]-6H-吡咯并[4,3,2-EF][2]苯并氮杂-6-酮
8-氟-1,3,4,5-四氢-2-[4-[(甲基氨基)甲基]苯基]-6H-吡咯并[4,3,2-EF][2]苯并氮杂卓-6-酮
AG014447
AG-14447
AG 014447
Rucaparib
PF-01367388
Rucaparib Base
AG 014447
AG014447
Rucaparib impurity
Rucaparib free base
物理化学性质
| 熔点 | 187 - 189°C |
| 沸点 | 625.2±55.0 °C(Predicted) |
| 密度 | 1.281 |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 酸度系数(pKa) | 14.10±0.20(Predicted) |
| 形态 | 黄色固体 |
| 颜色 | 淡黄色至黄色 |
| InChI | InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24) |
| InChIKey | HMABYWSNWIZPAG-UHFFFAOYSA-N |
| SMILES | N1C(=O)C2=CC(F)=CC3NC(C4=CC=C(CNC)C=C4)=C(C2=3)CC1 |
安全数据
| 危险性符号(GHS) |  GHS08 |
| 警示词 | 警告 |
| 危险性描述 | H361 |
| 防范说明 | P201-P202-P281-P308+P313-P405-P501 |
制备方法
![methyl (4-(8-fluoro-1-oxo-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-5-yl)benzyl)(methyl)carbamate](/CAS/20180906/GIF/880160-69-0.gif)
880160-69-0
283173-50-2
以化合物（CAS: 880160-69-0）为原料合成8-氟-2-(4-((甲胺基)甲基)苯基)-4,5-二氢-1H-氮杂卓并[5,4,3-cd]吲哚-6(3H)-酮的一般步骤如下： 实施例13：合成8-氟-2-(4-甲氨基甲基-苯基)-1,3,4,5-四氢-氮杂环庚烷并[5,4,3-cd]吲哚-6-酮（15） 将内酰胺14（14.42 g，0.038 mol）溶于氢溴酸的乙酸溶液（30%-32%，140 mL）中。反应溶液在室温下于500 mL烧瓶中搅拌46小时，烧瓶与乙醇胺洗涤器系统连接。HPLC分析确认反应完成。向反应溶液中加入冰（30 g），随后缓慢加入NaOH水溶液（327 mL，10 M，3.27 mol），同时控制温度在25℃至35℃之间。NaOH加入完成后，反应混合物的pH值为10。过滤收集所得固体，用水（2×50 mL）洗涤。将滤饼悬浮于水（125 mL）中，搅拌2小时。再次过滤收集固体，用水（2×25 mL）洗涤并干燥，得到产物10.76 g，收率88%。 产物表征： 1H NMR（300 MHz, DMSO-d6）δ 2.577（s, 3H）, 3.053（m, 2H）, 3.406（m, 2H）, 4.159（s, 2H）, 7.36（dd, 1H, J = 2.4 Hz和J = 9.3 Hz）, 7.44（dd, 1H, J = 2.4 Hz和J = 11.1 Hz）, 7.63（d, 2H, J = 8.1 Hz）, 7.70（d, 2H, J = 8.1 Hz）, 8.265（t, 1H, J = 5.7 Hz）, 11.77（s, 1H）。 计算值（C19H19FN3O）精确质量：324.1512。实测值：324.1497。
参考文献：
[1] Patent: US2006/63926, 2006, A1. Location in patent: Page/Page column 6; 11
鲁卡帕尼价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-10617A | 鲁卡帕尼 Rucaparib | 283173-50-2 | 5mg | 750元 |
| 2025/05/22 | HY-10617A | 鲁卡帕尼 Rucaparib | 283173-50-2 | 10mg | 1300元 |
| 2025/05/22 | HY-10617A | 鲁卡帕尼 Rucaparib | 283173-50-2 | 50mg | 3500元 |
常见问题列表
|
PARP-1 1.4 nM (Ki) |
Rucaparib is the most potent PARP inhibitor in enzyme assays (K i , 1.4 nM), and a possible N-demethylation metabolite of AG14644. The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells.
Rucaparib and AG14584 significantly (P < 0.05) increases temozolomide toxicity. Rucaparib (1 mg/kg) significantly increases temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) results in a 50% increase in the temozolomide-induced tumor growth delay. Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts.